Список литературы

1. Дедов И.И., Кураева Т.Л., Петеркова В.А. Сахарный диабет у детей и подростков. Москва: ГЭОТАР-Медиа, 2013. 271 p.

2. Петеркова В.А., Кураева Т.Л., Еремина И.А. Особенности диабета типа 2 у детей и подростков//Сахарный диабет типа 2: от теории к практике. Под редакцией академика РАН И.И. Дедова, члена-корреспондента РАН М.В. Шестаковой. Москва: ООО "Медицинское информационное агентство", 2016.

3. Dubinina I.A. et al. Studying progression from glucose intolerance to type 2 diabetes in obese children//Diabetes Metab. Syndr. Clin. Res. Rev. 2014. Vol. 8, N 3. P. 133 - 137.

4. Кураева Т.Л. et al. Проблемы диагностики и терапии сахарного диабета 2 типа у детей и подростков//Материалы V Городской научно-практическая конференции "Эндокринологические аспекты в педиатрии". Москва, 2011. P. 26 - 33.

5. Александрова Г.А. et al. Общая заболеваемость детского населения России (0 - 14 лет) в 2019 году. Статистические материалы. Часть VI. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ "ЦНИИОИЗ" Минздрава России, 2020.

6. Александрова Г.А. et al. Заболеваемость детского населения России (0 - 14 лет) в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. Часть V. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ "ЦНИИОИЗ" Минздрава России, 2020.

7. Александрова Г.А. et al. Заболеваемость детского населения России (15 - 17 лет) в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. Часть IX. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ "ЦНИИОИЗ" Минздрава России, 2020.

8. Александрова Г.А. et al. Общая заболеваемость детского населения России (15 - 17 лет) в 2019 году. Статистические материалы. Часть X. Москва: Департамент мониторинга, анализа и стратегического развития здравоохранения Минздрава России, ФГБУ "ЦНИИОИЗ" Минздрава России, 2020.

9. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. 2017. Vol. 1, N 20. P. 13 - 41.

10. Дедов И.И. et al. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 2013 - 2016 гг.//Сахарный Диабет. 2017. Vol. 20, N 6. P. 392 - 402.

11. Dabelea D. et al. Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009//JAMA. 2014. Vol. 311, N 17. P. 1778.

12. Libman I. et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents//Pediatr. Diabetes. 2022. Vol. 23, N 8. P. 1160 - 1174.

13. Dabelea D. et al. Etiological Approach to Characterization of Diabetes Type: The SEARCH for Diabetes in Youth Study//Diabetes Care. 2011. Vol. 34, N 7. P. 1628 - 1633.

14. Eremina I.A. et al. Clinical polymorphism of type 2 diabetes in children - the first study in Russia//Probl. Endocrinol. 2015. Vol. 61, N 6. P. 10 - 16.

15. Mayer-Davis E.J. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents//Pediatr. Diabetes. 2018. Vol. 19. P. 7 - 19.

16. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021//Diabetes Care. 2021. Vol. 44, N Supplement 1. P. S15 - S33.

17. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 2006.

18. Sabin M.A. Type 2 diabetes in children: Type 2 diabetes in children//Clin. Obes. 2013. Vol. 3, N 3 - 4. P. 112 - 116.

19. Klingensmith G.J. et al. The Presence of GAD and IA-2 Antibodies in Youth With a Type 2 Diabetes Phenotype: Results from the TODAY study//Diabetes Care. 2010. Vol. 33, N 9. P. 1970 - 1975.

20. Felton J.L. et al. Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review//Commun. Med. 2024. Vol. 4, N 1. P. 66.

21. Zeitler P. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth//Pediatr. Diabetes. 2018. Vol. 19. P. 28 - 46.

22. Petitti D.B. et al. Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study//J. Pediatr. 2009. Vol. 155, N 5. P. 668 - 672.e3.

23. Zeitler P. et al. HbA_1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes//Diabetes Care. 2015. Vol. 38, N 12. P. 2285 - 2292.

24. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018//Diabetes Care. 2018. Vol. 41, N Supplement 1. P. S73 - S85.

25. Еремина И.А., Кураева Т.Л. Метформин в лечении сахарного диабета 2-го типа у детей и подростков//Проблемы эндокринологии. 2013. N 1. P. 8 - 13.

26. Jones K.L. et al. Effect of Metformin in Pediatric Patients With Type 2 Diabetes: A randomized controlled trial//Diabetes Care. 2002. Vol. 25, N 1. P. 89 - 94.

27. TODAY Study Group et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes//N. Engl. J. Med. 2012. Vol. 366, N 24. P. 2247 - 2256.

28. Fath M. et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus: FATH et al.//Pediatr. Diabetes. 2017. Vol. 18, N 8. P. 903 - 910.

29. Bode B.W. et al. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial//Diabetes Care. 2019. Vol. 42, N 7. P. 1255 - 1262.

30. Battelino T. et al. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial//Pediatr. Diabetes. 2018. Vol. 19, N 7. P. 1263 - 1270.

31. Thalange N. et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes: IDeg effective and safe in pediatric T1D//Pediatr. Diabetes. 2015. Vol. 16, N 3. P. 164 - 176.

32. Danne T. et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes//Diabetes Care. 2005. Vol. 28, N 9. P. 2100 - 2105.

33. Philotheou A. et al. Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal-Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes//Diabetes Technol. Ther. 2011. Vol. 13, N 3. P. 327 - 334.

34. Holcombe J.H. et al. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents//Clin. Ther. 2002. Vol. 24, N 4. P. 629 - 638.

35. Tupola S. et al. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus//Diabet. Med. J. Br. Diabet. Assoc. 2001. Vol. 18, N 8. P. 654 - 658.

36. Deeb L.C. et al. Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes//PEDIATRICS. 2001. Vol. 108, N 5. P. 1175 - 1179.

37. Liu M. et al. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus//BMC Endocr. Disord. 2016. Vol. 16, N 1. P. 67.

38. Schober E. et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus//J. Pediatr. Endocrinol. Metab. JPEM. 2002. Vol. 15, N 4. P. 369 - 376.

39. Robertson K.J. et al. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes//Diabet. Med. J. Br. Diabet. Assoc. 2007. Vol. 24, N 1. P. 27 - 34.

40. Thalange N. et al. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials//Pediatr. Diabetes. 2019. Vol. 20, N 3. P. 314 - 320.

41. Danne T. et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes//Diabetes Care. 2003. Vol. 26, N 11. P. 3087 - 3092.

42. Danne T. et al. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6 - 17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial//Diabetes Care. 2020. Vol. 43, N 7. P. 1512 - 1519.

43. Predieri B. et al. Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes//Front. Endocrinol. 2018. Vol. 9. P. 462.

44. Дедов И.И. et al. Проект рекомендаций Российской ассоциации эндокринологов по применению биосимиляров инсулина. 2021. Vol. 24, N 1. P. 76 - 79.

45. Arslanian S. et al. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association//Diabetes Care. 2018. Vol. 41, N 12. P. 2648 - 2668.

46. Tamborlane W.V. et al. Liraglutide in Children and Adolescents with Type 2 Diabetes//N. Engl. J. Med. 2019. Vol. 381, N 7. P. 637 - 646.

47. Frid A.H. et al. New Insulin Delivery Recommendations//Mayo Clin. Proc. 2016. Vol. 91, N 9. P. 1231 - 1255.

48. Майоров А.Ю. et al. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. Москва: ООО "АРТИНФО", 2018. 64 p.

49. Smart C.E. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes//Pediatr. Diabetes. 2018. Vol. 19. P. 136 - 154.

50. American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018//Diabetes Care. 2018. Vol. 41, N Supplement 1. P. S38-S50.

51. Barlow S.E. Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report//Pediatrics. 2007. Vol. 120, N Supplement 4. P. S164 - S192.

52. Lien A.S.-Y. et al. A Systematic Review and Meta-Analysis of the Effect of Lifestyle Modification on Metabolic Control in Overweight Children//Evid. Based Complement. Alternat. Med. 2017. Vol. 2017. P. 1 - 12.

53. Dhuper S., Buddhe S., Patel S. Managing Cardiovascular Risk in Overweight Children and Adolescents//Pediatr. Drugs. 2013. Vol. 15, N 3. P. 181 - 190.

54. Jensen M.D. et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society//Circulation. 2014. Vol. 129, N 25 suppl 2. P. S102 - S138.

55. Chahal H. et al. Availability and night-time use of electronic entertainment and communication devices are associated with short sleep duration and obesity among Canadian children: EECD use and obesity among children//Pediatr. Obes. 2013. Vol. 8, N 1. P. 42 - 51.

56. Lane A., Harrison M., Murphy N. Screen Time Increases Risk of Overweight and Obesity in Active and Inactive 9-Year-Old Irish Children: A Cross Sectional Analysis//J. Phys. Act. Health. 2014. Vol. 11, N 5. P. 985 - 991.

57. Adolfsson P. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Exercise in children and adolescents with diabetes//Pediatr. Diabetes. 2018. Vol. 19. P. 205 - 226.

58. Glazier R.H. et al. A Systematic Review of Interventions to Improve Diabetes Care in Socially Disadvantaged Populations//Diabetes Care. 2006. Vol. 29, N 7. P. 1675 - 1688.

59. Nadeau K.J. et al. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities//Diabetes Care. 2016. Vol. 39, N 9. P. 1635 - 1642.

60. L. et al. Exaggerated Adrenarche and Hyperinsulinism in Adolescent Girls Born Small for Gestational Age//J. Clin. Endocrinol. Metab. 1999. Vol. 84, N 12. P. 4739 - 4741.

61. Dabelea D., Crume T. Maternal Environment and the Transgenerational Cycle of Obesity and Diabetes//Diabetes. 2011. Vol. 60, N 7. P. 1849 - 1855.

62. Yokoyama H. et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan//Kidney Int. 2000. Vol. 58, N 1. P. 302 - 311.

63. Stevens P.E., Levin A., Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline//Ann. Intern. Med. 2013. Vol. 158, N 11. P. 825 - 830.

64. Schwartz G.J. et al. New equations to estimate GFR in children with CKD//J. Am. Soc. Nephrol. JASN. 2009. Vol. 20, N 3. P. 629 - 637.

65. Schwartz G.J., Work D.F. Measurement and estimation of GFR in children and adolescents//Clin. J. Am. Soc. Nephrol. CJASN. 2009. Vol. 4, N 11. P. 1832 - 1843.

66. Copeland K.C. et al. Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline//J. Clin. Endocrinol. Metab. 2011. Vol. 96, N 1. P. 159 - 167.

67. TODAY Study Group. Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial//Diabetes Care. 2013. Vol. 36, N 6. P. 1735 - 1741.

68. Lewis E.J. et al. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy//N. Engl. J. Med. 1993. Vol. 329, N 20. P. 1456 - 1462.

69. Strippoli G.F.M. et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review//BMJ. 2004. Vol. 329, N 7470. P. 828.

70. Lv J. et al. Antihypertensive agents for preventing diabetic kidney disease//Cochrane Database Syst. Rev./ed. Cochrane Kidney and Transplant Group. 2012.

71. Strippoli G.F. et al. Antihypertensive agents for preventing diabetic kidney disease//Cochrane Database of Systematic Reviews/ed. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd, 2005. P. CD004136.pub2.

72. Wu H.-Y. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis//BMJ. 2013. Vol. 347, N oct 24 2. P. f6008 - f6008.

73. Barkai L, A, I. The effect of captopril therapy on the degree of microalbuminuria in diabetic children and adolescents with incipient nephropathy//Orv Hetil. 1996. Vol. 137, N 46. P. 2565 - 2568.

74. American Diabetes Association. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018//Diabetes Care. 2018. Vol. 41, N Supplement 1. P. S105 - S118.

75. Wong J. et al. Timing Is Everything: Age of Onset Influences Long-Term Retinopathy Risk in Type 2 Diabetes, Independent of Traditional Risk Factors//Diabetes Care. 2008. Vol. 31, N 10. P. 1985 - 1990.

76. Constantino M.I. et al. Long-Term Complications and Mortality in Young-Onset Diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes//Diabetes Care. 2013. Vol. 36, N 12. P. 3863 - 3869.

77. Donaghue K.C. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents//Pediatr. Diabetes. 2018. Vol. 19. P. 262 - 274.

78. Martinez-Zapata M.J. et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy//Cochrane Database Syst. Rev./ed. Cochrane Eyes and Vision Group. 2014.

79. Simunovic M.P., Maberley D.A.L. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis//Retina. 2015. Vol. 35, N 10. P. 1931 - 1942.

80. TODAY Study Group. Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial//Diabetes Care. 2013. Vol. 36, N 6. P. 1772 - 1774.

81. Rodriguez B.L. et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study//Diabetes Care. 2006. Vol. 29, N 8. P. 1891 - 1896.

82. Еремина И.А. et al. Кардиоваскулярная форма автономной нейропатии у подростков с сахарным диабетом 2 типа//Проблемы Эндокринологии. 2014. Vol. 60, N 5. P. 15 - 21.

83. Maffi P., Secchi A. The Burden of Diabetes: Emerging Data//Developments in Ophthalmology/ed. Bandello F. et al. S. Karger AG, 2017. Vol. 60. P. 1 - 5.

84. Jaiswal M. et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study//Pediatr. Diabetes. 2018.

85. Copeland K.C. et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents//PEDIATRICS. 2013. Vol. 131, N 2. P. 364 - 382.

86. EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report//PEDIATRICS. 2011. Vol. 128, N Supplement. P. S213 - S256.

87. TODAY Study Group. Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial//Diabetes Care. 2013. Vol. 36, N 6. P. 1758 - 1764.

88. Batisky D.L. What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?//Curr. Hypertens. Rep. 2012. Vol. 14, N 6. P. 603 - 607.

89. Blowey D.L. Update on the Pharmacologic Treatment of Hypertension in Pediatrics: Update on Pharmacologic Treatment in Pediatrics//J. Clin. Hypertens. 2012. Vol. 14, N 6. P. 383 - 387.

90. Legro R.S. et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline//J. Clin. Endocrinol. Metab. 2013. Vol. 98, N 12. P. 4565 - 4592.

91. Newton K.P. et al. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease//JAMA Pediatr. 2016. Vol. 170, N 10. P. e161971.

92. Nadeau K.J., Klingensmith G., Zeitler P. Type 2 Diabetes in Children is Frequently Associated with Elevated Alanine Aminotransferase://J. Pediatr. Gastroenterol. Nutr. 2005. Vol. 41, N 1. P. 94 - 98.

93. Sundaram S.S., Zeitler P., Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children://Curr. Opin. Pediatr. 2009. Vol. 21, N 4. P. 529 - 535.

94. Reinehr T. et al. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study//Arch. Dis. Child. 2009. Vol. 94, N 6. P. 437 - 442.

95. Angulo P. et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis//Hepatology. 1999. Vol. 30, N 6. P. 1356 - 1362.

96. Shaw J.E. et al. Sleep-disordered breathing and type 2 diabetes//Diabetes Res. Clin. Pract. 2008. Vol. 81, N 1. P. 2 - 12.

97. Foster G.D. et al. Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes//Diabetes Care. 2009. Vol. 32, N 6. P. 1017 - 1019.

98. Abraham M.B. et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes//Pediatr. Diabetes. 2018. Vol. 19. P. 178 - 192.

99. Tinti D., Rabbone I. Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series//Acta Diabetol. 2019.